Share

November 2019; 6 (6) ArticleOpen Access

Vitamin D enhances responses to interferon-β in MS

Xuan Feng, Zhe Wang, Quentin Howlett-Prieto, Nathan Einhorn, Suad Causevic, Anthony T. Reder
First published October 3, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000622
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
974

Share

Article Information

vol. 6 no. 6 e622
DOI: 
https://doi.org/10.1212/NXI.0000000000000622
PubMed: 
31582399
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 8, 2019
  • Accepted in final form August 13, 2019
  • First Published October 3, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Xuan Feng, PhD*,
    2. Zhe Wang, MD, PhD*,
    3. Quentin Howlett-Prieto, BS,
    4. Nathan Einhorn, BA,
    5. Suad Causevic, BA and
    6. Anthony T. Reder, MD
  1. Xuan Feng, PhD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Zhe Wang, MD, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Quentin Howlett-Prieto, BS,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Nathan Einhorn, BA,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Suad Causevic, BA and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Anthony T. Reder, MD
    7. Scientific Advisory Boards:

    1. (1) Abbott, ImmunoScience, Inc., (2) Questcor/Malinkrodt, (3) AstraZeneca, (4)Merck Serono, (5) Athena Diagnostics, Inc., (6) Sanofi-Aventis, (7) Bayer, (8) Biogen Idec, (9) BioMS Medical, (10) Blue Cross Blue Shield, (11) Boehringer Ingelheim, (12) Caremark Rx, (13) Centocor Ortho Biotech Inc., (14) Cephalon, Inc., (15) Connetics Corp., (16) CroMedica Global Inc., (17) Eli Lilly and Company, (18) Elan Corporation, (19) Genentech, Inc., (20) Genzyme Corporation, (21) GlaxoSmithKline, (22) Hoechst Marion Roussel Canada Research, Inc., (23) Roche, (24) Immunex Corporation, (25) Institute for Health Care Quality, (26) Johnson & Johnson, (27) Yale University, (28) Barrow Neurological Institute, (29) National Multiple Sclerosis Society & Paralyzed Veterans of America, (30) Neurocrine Biosciences, (31) Novartis, (32) Parke-Davis, (33) Pfizer Inc., (34) Pharmacia & Upjohn, (35) Protein Design Labs, Inc., (36) Quantum Biotechnologies, Inc., (37) Quintiles, Inc., (38) EMD Serono, Inc., (39 Sention, Inc., (40) Smith Kline- Beecham, (41) Specialized Therapeutics (a division of Berlipharm, Inc.), (42) Takeda Pharmaceutical Company Limited, (43) Teva Pharmaceutical Industries Ltd.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Abbott, ImmunoScience, Inc., (2) Questcor/Malinkrodt, (3) AstraZeneca, (4)Merck Serono, (5) Athena Diagnostics, Inc., (6) Sanofi-Aventis, (7) Bayer Schering Pharma, (8) Biogen Idec, (9) BioMS Medical, (10) Blue Cross Blue Shield, (11) Boehringer Ingelheim, (12) Caremark Rx, (13) Centocor Ortho Biotech Inc., (14) Cephalon, Inc., (15) Connetics Corp., (16) CroMedica Global Inc., (17) Eli Lilly and Company, (18) Elan Corporation, (19) Genentech, Inc., (20) Genzyme Corporation, (21) GlaxoSmithKline, (22) Hoechst Marion Roussel Canada Research, Inc., (23) Roche, (24) Immunex Corporation, (25) Institute for Health Care Quality, (26) Johnson & Johnson, (27) Yale University, (28) Barrow Neurological Institute, (29) National Multiple Sclerosis Society & Paralyzed Veterans of America, (30) Neurocrine Biosciences, (31) Novartis, (32) Parke-Davis, (33) Pfizer Inc., (34) Pharmacia & Upjohn, (35) Protein Design Labs, Inc., (36) Quantum Biotechnologies, Inc., (37) Quintiles, Inc., (38) EMD Serono, Inc., (39 Sention, Inc., (40) Smith Kline- Beecham, (41) Specialized Therapeutics (a division of Berlipharm, Inc.), (42) Takeda Pharmaceutical Company Limited, (43) Teva Pharmaceutical Industries Ltd.

    Editorial Boards:

    1. (1) Medlink/Neurobase Editorial Board, Arbor Publishing Corporation, San Diego, CA, 1999-Present; (2) Turkish Journal of Medical Sciences, Editorial Board, 2001- present; (3) Türk Nöroloji Dergisi (Turkish Journal of Neurology), Editorial Board, 2004-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbott, (2) Questcor/Malinkrodt,(3) AstraZeneca, (4) Merck Serono, (5) Athena Diagnostics, Inc., (6) Sanofi- Aventis, (7) Bayer Schering Pharma, (8) Biogen Idec, (9) BioMS Medical, (10) Blue Cross Blue Shield, (11) Boehringer Ingelheim, (12) Caremark Rx, (13) Centocor Ortho Biotech Inc., (14) Cephalon, Inc., (15) Connetics Corp., (16) CroMedica Global Inc., (17) Eli Lilly and Company, (18) Elan Corporation, (19) Genentech, Inc., (20) Genzyme Corporation, (21) GlaxoSmithKline, (22) Hoechst Marion Roussel Canada Research, Inc., (23) Roche, (24) Immunex Corporation, (25) Institute for Health Care Quality, (26) Johnson & Johnson, (27) Yale University, (28) Barrow Neurological Institute, (29) National Multiple Sclerosis Society & Paralyzed Veterans of America, (30) Neurocrine Biosciences, (30.5) NIH (31) Novartis, (32) Parke-Davis, (33) Pfizer Inc., (34) Pharmacia & Upjohn, (35) Protein Design Labs, Inc., (36) Quantum Biotechnologies, Inc., (37) Quintiles, Inc., (38) EMD Serono, Inc., (39 Sention, Inc., (40) Smith Kline- Beecham, (41) Specialized Therapeutics (a division of Berlipharm, Inc.), (42) Takeda Pharmaceutical Company Limited, (43) Teva Pharmaceutical Industries Ltd.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis, (2) Bayer, (3) Serono, Inc., (4) Chugai, (5) Genzyme,(6) Biogen Idec, (7)Medimmune (8) Genentech/Roche, Inc., (8) Medday

    Research Support, Government Entities:

    1. (1) NIH/NINDS RO1 NS 051591, Site PI; (2) NIH 1 K24 RR021948, PI. (2) Chinese Government, (3) Turkish Ministry of Defense Fellowship Award, (4) the State of Illinois

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) the National MS Society, (2) the Brain Research Foundation, (3) the American Academy of Allergy & Immunology, (4) Howard Hughes Foundation, (5) Egypt Arab Republic Peace Fellowship,

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (X.F., Q.H.-P., N.E., S.C., A.T.R.), University of Chicago Medicine, IL; and Department of Neurology (Z.W.), The First Affiliated Hospital of Dalian Medical University, China.
  1. Correspondence
    Dr. Reder areder{at}neurology.bsd.uchicago.edu
View Full Text

Article usage

Article usage: October 2019 to January 2023

AbstractFullPdfSource
Oct 201939241102Highwire
Nov 201910612355Highwire
Dec 2019792655Highwire
Jan 2020538623Highwire
Feb 20201224122Highwire
Mar 2020728019Highwire
Apr 2020282521Highwire
May 2020362539Highwire
Jun 2020234728Highwire
Jul 2020225333Highwire
Aug 2020316221Highwire
Sep 20201345819Highwire
Oct 2020918429Highwire
Nov 2020317531Highwire
Dec 2020615615Highwire
Jan 2021415129Highwire
Feb 202186414Highwire
Mar 202158833Highwire
Apr 202179019Highwire
May 202129118Highwire
Jun 202166925Highwire
Jul 202186110Highwire
Aug 202127018Highwire
Sep 2021410715Highwire
Oct 2021610726Highwire
Nov 202145523Highwire
Dec 202145210Highwire
Jan 202218314Highwire
Feb 202267216Highwire
Mar 2022624520Highwire
Apr 202275921Highwire
May 2022570732Highwire
Jun 2022221615Highwire
Jul 20222888Highwire
Aug 20225849Highwire
Sep 202268422Highwire
Oct 202288216Highwire
Nov 202289720Highwire
Dec 202213013Highwire
Jan 202375516Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me